☀️     🌓

Prescribing Advice for GPs

An NHS Prescribing Advisers' Blog

EVRA linked to VTE

The Food and Drugs Administration has updated prescribing information for the contraceptive patch (EVRA®) after studies found an increased risk of venous thromboembolism (VTE) when compared to combined oral contraceptive tablets (COCs).

According to information on the manufacturers website there have been four epidemiological studies comparing the patch to oral contraceptives. Two of these studies found no difference in risk while two have found an approximate doubling of risk.

The Summary of Product Characteristics (SPC) available in the UK states that, "currently there is no evidence to exclude that EVRA may be more thrombogenic than combined oral contraceptives". The SPC also states that this product should not be used in patients with a history of venous thromboembolism.

Action: When discussing contraceptive options, clinicians should ensure that patients are made aware of the increased risk of VTE with EVRA compared to COCs.

Share 'EVRA linked to VTE' by emailShare 'EVRA linked to VTE' on FacebookShare 'EVRA linked to VTE' on TwitterShare 'EVRA linked to VTE' on LinkedInShare 'EVRA linked to VTE' on reddit


No Comments to “EVRA linked to VTE”

Leave a Comment

Your email address will not be published. Required fields are marked *

Please be aware that you comment is subject to our Privacy Policy.

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Prescribing Advice for GPs is powered by ClassicPress.
Connect to our RSS or Atom Feeds.